iBio (NYSE:IBIO) Now Covered by Brookline Capital Management

Equities research analysts at Brookline Capital Management initiated coverage on shares of iBio (NYSE:IBIO) in a research note issued to investors on Monday, Benzinga reports. The brokerage set a “buy” rating and a $3.60 price target on the stock. Brookline Capital Management’s price target suggests a potential upside of 56.52% from the company’s previous close.

IBIO has been the topic of a number of other reports. StockNews.com started coverage on shares of iBio in a report on Saturday, April 20th. They issued a “sell” rating on the stock. Chardan Capital reiterated a “buy” rating and set a $5.00 price objective on shares of iBio in a research report on Monday, June 3rd.

iBio Price Performance

iBio stock opened at $2.30 on Monday. iBio has a 52 week low of $1.02 and a 52 week high of $15.99. The firm’s 50-day moving average is $2.21. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.69 and a current ratio of 1.69.

iBio (NYSE:IBIO) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.71) EPS for the quarter. Equities research analysts forecast that iBio will post -99.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Ikarian Capital LLC purchased a new position in iBio during the 1st quarter worth approximately $2,436,000. Opaleye Management Inc. purchased a new position in shares of iBio during the first quarter valued at $2,761,000. Finally, Lynx1 Capital Management LP acquired a new position in iBio during the first quarter valued at $2,436,000. 7.90% of the stock is owned by hedge funds and other institutional investors.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.